BRCA2 and cancer: The pCR rate was 38.3% [95% CI, 26%–55%] among BRCA1 mutation carriers, and 66% among the 6 BRCA2 mutation carriers. 15 relapses and 6 s cancers were recorded during the follow-up period. 11 deaths occurred, all of which were in the non-pCR group. DFS (p < 0.01) and OS (p < 0.01) were significantly better in the pCR group than the non-pCR group.